

URGENT PRODUCT ALERT H.P. Acthar® Gel

July 2, 2007

Dear Healthcare Professional,

As you know, H.P. Acthar[®] Gel (repository corticotropin injection) plays a critical role in many inpatient and outpatient treatment regimens. Effective August 1, 2007, Acthar Gel (NDC # 63004-7731-1) will be available exclusively through Specialty Pharmacy Distribution. Acthar Gel will no longer be available from traditional pharmaceutical wholesalers or retail pharmacies. Please be sure to share this information appropriately with your staff and patients.

For Hospital Stock Orders

Beginning July 16, 2007, hospitals should place all stock orders with CuraScript Specialty Distribution (877-599-7748). We suggest that appropriate personnel at your facility contact CuraScript Specialty Distribution (877-599-7748) as soon as possible to establish an account.

Planning for Patient Discharge – Outpatient Prescriptions

Beginning July 16, 2007, when treatment with Acthar Gel is initiated in a hospital setting with the intent to continue after discharge, it is imperative that the outpatient prescription order be placed immediately after treatment initiation to ensure an uninterrupted supply of Acthar Gel at discharge. Beginning July 16, 2007, please contact the following support and access program to get prescriptions filled and for assistance with reimbursement:

Acthar Support & Access Program (ASAP)

PHONE: 888-435-2284
 FAX: 877-937-2284

More information and referral forms can be obtained at www.acthar.com.

Filling Prescriptions

Please tell your patients currently having Acthar Gel prescriptions filled at retail pharmacies to immediately confirm the pharmacy has stock on hand for their remaining refills. Beginning July 16, 2007, all new Acthar Gel prescriptions should be submitted to the Acthar Support & Access Program (PHONE: 888-435-2284; FAX: 877-937-2284).

Questcor is committed to providing uninterrupted availability of Acthar Gel for patients who critically need it. This change in Acthar Gel distribution and the creation of the Acthar Support & Access Program is an important part of this mission.

Sincerely,

Steve Cartt, Executive Vice President, Corporate Development Questcor Pharmaceuticals